Sorrento Therapeutics Inc

NASDAQ:SRNE   3:07:25 PM EDT
6.66
+0.31 (+4.88%)
Products

Sorrento Receives FDA Clearance To Proceed With Phase 2 Study For Sti-3031 For Advanced Urothelial Carcinoma

Published: 04/27/2021 16:15 GMT
Sorrento Therapeutics Inc (SRNE) - Sorrento Receives FDA Clearance to Proceed With Phase 2 Study for Sti-3031, an Anti-pd-l1 Antibody, for Advanced Urothelial Carcinoma.